I now have very rich data from multiple authoritative sources. Let me compile the comprehensive comparison.
Type 1 Diabetes Mellitus vs Type 2 Diabetes Mellitus - Detailed Comparison
1. Overview / Definition
| Feature | Type 1 DM (T1DM) | Type 2 DM (T2DM) |
|---|
| Core defect | Absolute insulin deficiency due to destruction of pancreatic beta cells | Insulin resistance with relative (not absolute) insulin deficiency |
| Proportion of all DM | ~5-10% of cases | ~90-95% of all cases |
| Former names | Juvenile-onset DM, Insulin-dependent DM (IDDM) | Adult-onset DM, Non-insulin-dependent DM (NIDDM) |
2. Etiology & Pathogenesis
Type 1 DM
- Autoimmune destruction of beta cells in the pancreatic islets of Langerhans, resulting in complete loss of insulin production.
- Environmental triggers (viral infections, toxins, possibly vitamin D deficiency) may initiate the autoimmune cascade in genetically predisposed individuals.
- A prediabetes period of gradual beta cell destruction can last months to decades. During this silent phase, the first-phase insulin release to IV glucose becomes depressed or absent.
- Eventually, most or all beta cells are destroyed, causing undetectable C-peptide and insulin levels. - Henry's Clinical Diagnosis and Management by Laboratory Methods
Autoantibodies found in T1DM:
- Anti-GAD65 (glutamic acid decarboxylase) - highest sensitivity (91%) as a single screening marker
- Insulin autoantibodies (IAA) - more common in young children
- IA-2 (insulinoma-associated protein 2, tyrosine phosphatase)
- ZnT8A (zinc transporter 8) - located on secretory granule surface membranes
Individuals with ≥2 autoantibodies are at significantly increased risk of developing T1DM. - Henry's Clinical Diagnosis
Type 2 DM
- Caused by insulin resistance combined with progressive beta cell dysfunction. Genetic susceptibility (≥18 polymorphisms identified by GWAS) interacts with environmental triggers.
- Genetically susceptible individuals develop obesity, which induces physiologic stress and overproduction of insulin. Over time, programmed beta cell apoptosis begins.
- By the time prediabetes is diagnosed (2-hour postprandial glucose 140-180 mg/dL), patients have already lost ~80% of beta cell function and are maximally insulin resistant. - Textbook of Family Medicine
- Disease is progressive - ultimately requires multiple agents and often insulin.
- Environmental triggers include obesity, high-fat diet, physical inactivity, vitamin D deficiency, concurrent illness, and certain medications (glucocorticoids, HIV medications). - Textbook of Family Medicine
3. Insulin Release Pattern
The graph below from Lippincott's Pharmacology perfectly illustrates the key difference:
Figure: Release of insulin in response to an IV glucose load. Normal subjects show a sharp first-phase peak; Type 2 shows a blunted, delayed response; Type 1 shows a near-flat line. (Lippincott Illustrated Reviews: Pharmacology)
- T1DM: No first-phase or second-phase insulin release - pancreas cannot respond to glucose at all.
- T2DM: Loss of the early first-phase peak; slow, blunted second-phase response - insulin is still produced but insufficiently and with poor timing.
4. Epidemiology & Risk Factors
| Feature | T1DM | T2DM |
|---|
| Age at onset | Typically childhood, adolescence, young adults (can occur at any age; LADA appears in adults) | Typically >45 years, increasingly younger |
| Body habitus | Usually normal weight or thin | Usually overweight or obese |
| Sex | Roughly equal | Slightly more common in women with certain risk factors (PCOS, gestational DM history) |
| Ethnicity | Any; slight North European predominance | Higher in African Americans, Native Americans, Hispanics, Asians, Pacific Islanders |
| Family history | Weaker (3-5% risk if parent affected) | Stronger (1st degree relative is major risk factor) |
| Metabolic syndrome | Not typically associated | Strongly associated (HTN, dyslipidemia, abdominal obesity) |
| Other autoimmune diseases | Frequently associated (thyroid, celiac, Addison's) | Not typically associated |
5. Genetic Basis
| T1DM | T2DM |
|---|
| Key genes | HLA-DR3, HLA-DR4 (chromosome 6); also non-HLA genes | ≥18 polymorphisms identified; no single HLA association |
| HLA association | Strong (HLA-DR/DQ on chromosome 6) | Weak / absent |
| Mode | Polygenic + environmental trigger | Polygenic + strong environmental influence (obesity, diet) |
- T2DM polymorphisms favor reduced satiety, increased appetite, reduced energy expenditure, and increased intraabdominal fat - Textbook of Family Medicine
6. Clinical Presentation
| Feature | T1DM | T2DM |
|---|
| Onset | Acute / abrupt | Insidious (often asymptomatic at diagnosis) |
| Classic symptoms (3 Ps) | Polyuria, polydipsia, polyphagia - often dramatic and rapid | Often absent or subtle - many found on screening |
| Weight | Weight loss | Often overweight or obese |
| Ketonemia/DKA | Common - prone to DKA when insulin withheld | Rare - not prone to DKA; prone to HHS instead |
| At diagnosis | Often symptomatic, may present in DKA | Often asymptomatic; complications (e.g., retinopathy) may already be present |
7. Laboratory / Diagnostic Features
Shared diagnostic criteria (same for both types) - Swanson's Family Medicine Review / Miller's Anesthesia:
- Fasting plasma glucose ≥126 mg/dL (8-hour fast, confirmed on repeat)
- Random glucose ≥200 mg/dL + symptoms of hyperglycemia
- 2-hour plasma glucose ≥200 mg/dL during 75g OGTT
- HbA1c ≥6.5%
Distinguishing laboratory features:
| Lab Finding | T1DM | T2DM |
|---|
| C-peptide | Very low or undetectable | Normal or elevated (especially early); low in late-stage |
| Insulin levels | Very low / absent | Normal, elevated (early); reduced (late) |
| Autoantibodies (GAD65, IA-2, IAA, ZnT8A) | Positive (usually ≥2) | Negative |
| HbA1c monitoring | Target <7% (gold standard) | Same target |
| Prediabetes range | FPG 100-125 mg/dL; OGTT 140-199 mg/dL; HbA1c 5.7-6.4% | Same criteria |
8. Acute Complications
| Complication | T1DM | T2DM |
|---|
| Diabetic Ketoacidosis (DKA) | Common, hallmark - due to absolute insulin deficiency causing unrestrained lipolysis and ketogenesis | Rare (may occur in severe illness) |
| Hyperosmolar Hyperglycemic State (HHS) | Rare | More common - due to relative insulin sufficiency preventing ketosis but not hyperglycemia |
| Hypoglycemia | More frequent (tight insulin control) | Less frequent overall; occurs with insulin or sulfonylurea use |
| Hypoglycemic unawareness | Can develop with repeated episodes | Can develop similarly |
- Miller's Anesthesia: "T1DM patients prone to ketoacidosis when insulin is withheld; T2DM patients prone to HHS during acute illness."
9. Chronic Complications (Shared, but timing differs)
Both types share the same spectrum of complications, but in T2DM, complications may already be present before diagnosis due to the insidious onset:
Microvascular (from chronic hyperglycemia):
- Diabetic retinopathy - leading cause of blindness
- Diabetic nephropathy - T2DM is the most common cause of chronic renal failure in the US (because T2DM is 10x more frequent)
- Diabetic neuropathy (peripheral + autonomic)
Macrovascular (atherosclerotic):
-
Coronary heart disease
-
Peripheral vascular disease
-
Stroke / cerebrovascular disease
-
Endothelial dysfunction from hyperglycemia, AGE formation, elevated free fatty acids, oxidative stress, and insulin resistance drives both micro- and macrovascular disease. - Henry's Clinical Diagnosis
In T2DM, 18% of patients with prediabetes already have diabetic retinopathy before progressing to frank T2DM. - Textbook of Family Medicine
10. Treatment
Type 1 DM
Insulin is mandatory - there is no alternative. The goal is to mimic physiologic insulin secretion with:
| Delivery Method | Description |
|---|
| Multiple Daily Injections (MDI) | Basal + prandial (bolus) dosing regimen |
| Continuous Subcutaneous Insulin Infusion (CSII) / Insulin pump | Manual bolus entries |
| Sensor-Augmented Pump | CGM + pump; suspends insulin when glucose is low |
| Automated Insulin Delivery (AID) | CGM + pump + algorithm; adjusts basal rate in real-time |
Insulin types used:
- Rapid-acting (Aspart, Lispro, Glulisine): onset <15 min, peak 0.5-1.5h, duration 3-5h
- Short-acting (Regular): onset 0.5-1h, peak 2-3h, duration 4-8h
- Intermediate (NPH): onset 2-4h, peak 4-10h, duration 10-16h
- Long-acting (Glargine, Detemir, Degludec): onset 1-9h, flat/no peak, duration 20-24h+
- Harrison's Principles of Internal Medicine 22E
Type 2 DM
Stepwise, progressive pharmacologic approach centered on lifestyle first, then oral agents, then injectable therapy:
| Drug Class | Example | Mechanism |
|---|
| Biguanides (1st-line) | Metformin | Reduces hepatic gluconeogenesis, modest increase in peripheral uptake; promotes weight loss |
| Sulfonylureas | Glipizide, Glimepiride | Stimulate beta cell insulin secretion (ATP-K+ channel) |
| Meglitinides | Repaglinide | Short-acting insulin secretagogues |
| Thiazolidinediones | Pioglitazone | Insulin sensitizers (PPARγ agonists) |
| Alpha-glucosidase inhibitors | Acarbose | Delay carbohydrate absorption |
| DPP-4 inhibitors | Sitagliptin | Increase incretin levels → glucose-dependent insulin secretion |
| GLP-1 receptor agonists | Semaglutide, Liraglutide | Stimulate glucose-dependent insulin secretion, suppress glucagon, promote weight loss, CV benefit |
| SGLT-2 inhibitors | Empagliflozin, Dapagliflozin | Promote urinary glucose excretion; CV and renal protective benefits |
| Insulin | All types | When oral agents insufficient or in severe hyperglycemia |
- Metformin remains first-line; SGLT-2 inhibitors and GLP-1 agonists are preferred add-ons when CV/renal protection is needed - Harrison's 22E
- 15-20% of T2DM patients ultimately require insulin - Swanson's Family Medicine Review
11. Monitoring Targets (Both Types)
| Parameter | Target |
|---|
| HbA1c | <7.0% (gold standard; checked every 3 months) |
| Fasting plasma glucose | 80-130 mg/dL |
| Post-meal glucose (2h) | <180 mg/dL |
| Blood pressure | <130/80 mmHg |
| LDL cholesterol | <70 mg/dL (high CV risk) |
12. Summary Comparison Table
| Feature | Type 1 DM | Type 2 DM |
|---|
| Mechanism | Autoimmune beta cell destruction | Insulin resistance + progressive beta cell failure |
| Insulin | Absolute deficiency | Relative deficiency |
| Proportion | 5-10% | 90-95% |
| Onset | Acute, abrupt | Insidious, often asymptomatic |
| Age | Usually <30 years (any age) | Usually >45 years (decreasing) |
| Body weight | Normal/thin | Obese |
| Autoantibodies | Present (GAD65, IA-2, ZnT8A, IAA) | Absent |
| C-peptide | Very low/absent | Normal to high (early) |
| HLA association | Strong (DR3/DR4) | Weak/absent |
| Ketosis/DKA | Prone | Rare |
| HHS | Rare | Prone |
| Hypoglycemia risk | Higher | Lower (unless on insulin/SU) |
| Metabolic syndrome | Not associated | Strongly associated |
| Other autoimmune | Frequently co-exists | Not typically |
| Treatment | Insulin always required | Lifestyle → Metformin → add-on agents → insulin |
| Progression | Stable (beta cells already destroyed) | Progressive over years/decades |
| Complications | Same spectrum; earlier if poor control | Same spectrum; may predate diagnosis |
Sources
- Harrison's Principles of Internal Medicine, 22E (2025)
- Lippincott Illustrated Reviews: Pharmacology
- Henry's Clinical Diagnosis and Management by Laboratory Methods
- Miller's Anesthesia, 10E
- Textbook of Family Medicine, 9E
- Swanson's Family Medicine Review
